Certara (NASDAQ:CERT) PT Lowered to $20.00 at KeyCorp

Certara (NASDAQ:CERTGet Free Report) had its price target dropped by investment analysts at KeyCorp from $23.00 to $20.00 in a research report issued to clients and investors on Thursday, Benzinga reports. The firm presently has an “overweight” rating on the stock. KeyCorp’s price objective would suggest a potential upside of 44.09% from the stock’s previous close.

CERT has been the subject of several other reports. Barclays lowered their price objective on Certara from $18.00 to $16.00 and set an “equal weight” rating for the company in a research report on Friday, June 28th. JMP Securities restated a “market perform” rating on shares of Certara in a report on Wednesday. Seven research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $19.44.

View Our Latest Research Report on CERT

Certara Stock Performance

CERT opened at $13.88 on Thursday. The firm’s fifty day simple moving average is $15.58 and its two-hundred day simple moving average is $16.70. Certara has a 52-week low of $11.81 and a 52-week high of $19.87. The company has a market cap of $2.23 billion, a price-to-earnings ratio of -35.59, a PEG ratio of 4.93 and a beta of 1.52. The company has a quick ratio of 3.26, a current ratio of 3.26 and a debt-to-equity ratio of 0.27.

Certara (NASDAQ:CERTGet Free Report) last posted its quarterly earnings data on Tuesday, May 7th. The company reported $0.06 EPS for the quarter, missing the consensus estimate of $0.07 by ($0.01). Certara had a negative net margin of 17.02% and a positive return on equity of 4.08%. The firm had revenue of $96.65 million during the quarter, compared to analyst estimates of $94.48 million. Equities analysts anticipate that Certara will post 0.28 earnings per share for the current fiscal year.

Institutional Trading of Certara

A number of hedge funds and other institutional investors have recently bought and sold shares of CERT. Pineridge Advisors LLC acquired a new stake in shares of Certara during the 4th quarter worth about $28,000. Global Retirement Partners LLC lifted its position in shares of Certara by 5,306.3% during the 1st quarter. Global Retirement Partners LLC now owns 1,730 shares of the company’s stock worth $31,000 after buying an additional 1,698 shares during the last quarter. YHB Investment Advisors Inc. acquired a new position in shares of Certara in the 1st quarter valued at $47,000. Pacer Advisors Inc. grew its position in shares of Certara by 1,704.0% in the 4th quarter. Pacer Advisors Inc. now owns 12,754 shares of the company’s stock valued at $224,000 after buying an additional 12,047 shares during the last quarter. Finally, Capstone Investment Advisors LLC purchased a new stake in Certara in the first quarter valued at $245,000. 73.96% of the stock is currently owned by institutional investors and hedge funds.

Certara Company Profile

(Get Free Report)

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.

See Also

Analyst Recommendations for Certara (NASDAQ:CERT)

Receive News & Ratings for Certara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Certara and related companies with MarketBeat.com's FREE daily email newsletter.